Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9024089 | 0.81 | OPRM1 (0.56) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL8776633 | 0.79 | OPRM1 (0.58) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| Hydrochloric Acid SCHEMBL9057752 | 0.78 | OPRM1 (0.57) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL9471123 | 0.76 | SIGMAR1 (0.57) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL9653759 | 0.75 | OPRM1 (0.65) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL20745434 | 0.74 | DRD2 (0.59) | ACHESIGMAR1 | |
| SCHEMBL9030647 | 0.74 | SIGMAR1 (0.67) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL31210944 | 0.73 | HSD11B1 (0.48) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL14276915 | 0.72 | OPRM1 (0.58) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL9651081 | 0.72 | OPRM1 (0.61) | OPRM1CHRM2CHRM3ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-2013044361-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | OPRM1 4402/4885CHRM2 4825/4885CHRM3 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.